Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets

被引：1
|
作者：
Dalakoti, Mayank [1 ,2 ,3 ]
Virani, Salim [4 ,5 ,6 ]
机构：
[1] Natl Univ Heart Ctr, Dept Cardiol, Singapore, Singapore
[2] Ng Teng Fong Gen Hosp, Dept Med, Singapore, Singapore
[3] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England
[4] Aga Khan Univ, Dept Med, Karachi, Pakistan
[5] Texas Heart Inst, Houston, TX USA
[6] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX USA
来源：
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2024年 / 19卷
关键词：
Keywords; LDL-C; Primary prevention; Primordial prevention; Preventive cardiology; Lipids; CHOLESTEROL; MANAGEMENT;
D O I：
10.1016/j.ajpc.2024.100720
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors
    Ioannidis, John P. A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (05): : 419 - 420
  • [32] Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70-100 mg/dL in Taiwan
    Lin, Fang-Ju
    Shyu, Kou-Gi
    Hsieh, I-Chang
    Sheu, Wayne Huey-Herng
    Tu, Shih-Te
    Yeh, Shoou-Jeng
    Chen, Chin-, I
    Lu, Kuo-Cheng
    Wu, Chia-Chao
    Shau, Wen-Yi
    Inocencio, Timothy J.
    Wen, Yao-Chun
    Yeh, Hung-, I
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (05) : 907 - 916
  • [33] Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study
    Lehrke, Michael
    Vogt, Anja
    Schettler, Volker
    Girndt, Matthias
    Fraass, Uwe
    Tabbert-Zitzler, Anja
    Bridges, Ian
    Dhalwani, Nafeesa N.
    Ray, Kausik K.
    ADVANCES IN THERAPY, 2024, 41 (03) : 1184 - 1200
  • [34] Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study
    Michael Lehrke
    Anja Vogt
    Volker Schettler
    Matthias Girndt
    Uwe Fraass
    Anja Tabbert-Zitzler
    Ian Bridges
    Nafeesa N. Dhalwani
    Kausik K. Ray
    Advances in Therapy, 2024, 41 : 1184 - 1200
  • [35] Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study
    Yao, Tianci
    Lu, Weilin
    Ke, Jinshan
    Zhang, Hao
    Zhao, Xiaofang
    Song, Bei
    Liu, Ting
    Ke, Qinmei
    Liu, Chengyun
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [36] Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid
    Mascarenhas-Melo, Filipa
    Palavra, Filipe
    Marado, Daniela
    Sereno, Jose
    Teixeira-Lemos, Edite
    Freitas, Isabel
    Isabel-Mendonca, Maria
    Pinto, Rui
    Teixeira, Frederico
    Reis, Flavio
    SCIENTIFIC WORLD JOURNAL, 2013,
  • [37] Cardiovascular Risk Assessment and Control in Outpatients Evaluated by 24-hour Ambulatory Blood Pressure and Different LDL-C Equations
    Landolfo, Matteo
    Allevi, Massimiliano
    Spannella, Francesco
    Giulietti, Federico
    Gezzi, Alessandro
    Sarzani, Riccardo
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2023, 30 (06) : 551 - 560
  • [38] Cardiovascular Risk Assessment and Control in Outpatients Evaluated by 24-hour Ambulatory Blood Pressure and Different LDL-C Equations
    Matteo Landolfo
    Massimiliano Allevi
    Francesco Spannella
    Federico Giulietti
    Alessandro Gezzi
    Riccardo Sarzani
    High Blood Pressure & Cardiovascular Prevention, 2023, 30 : 551 - 560
  • [39] Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
    Korman, Max
    Wisloff, Torbjorn
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2018, 4 (01) : 15 - 22
  • [40] Lipid-Lowering Therapy and LDL-C Control for Primary Prevention in Persons With Diabetes Across 90 Health Systems in the United States
    Decicco, Emily
    Peterson, Eric D.
    Gupta, Anand
    Gillard, Kristin
    Sarnes, Evelyn
    Navar, Ann Marie M.
    CIRCULATION, 2023, 148
12345